Drug Database
S-

S-amlodipine gentisate (Nexad / Nexad TAb)

✓ Approved

SK Chemicals · CACNA1C · Small Molecule

What is S-amlodipine gentisate?

S-amlodipine gentisate is a small molecule developed by SK Chemicals. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesNexad, Nexad TAb
CompanySK Chemicals
Drug ClassSmall Molecule
Molecular TargetCACNA1C
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, SK Chemicals

Mechanism of Action

Molecular Targets

S-amlodipine gentisate acts on 1 molecular target:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

S-amlodipine gentisate is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Cardiac disordersAngina pectoris✓ Approved
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedClinical therapeutics2026-06-09

Efficacy and Safety Profile of a Triple Single-Pill Combination of Valsartan/Amlodipine/Chlorthalidone in Patients with Uncontrolled Hypertension.

Lee Hae-Young HY, Suh Soon-Yong SY, Youn Ho-Joong HJ, Chung Woo-Baek WB et al.

This randomized, double-blind, multicenter Phase III study evaluated the efficacy and safety profile of a single-pill triple combination of valsartan/amlodipine/chlorthalidone (KDF1901, Valdipine Plus) compared with a dual combination of valsartan/amlodipine (KDF1901-R) in patients with essential hypertension. Patients (n = 294) with inadequately controlled hypertension after a 4-week run-in phase with valsartan/amlodipine (80/5 mg) were randomized to receive KDF1901 (valsartan/amlodipine/chlorthalidone 160/10/25 mg, n = 147) or KDF1901-R (valsartan/amlodipine 160/10 mg, n = 147) for 8 weeks. The primary efficacy endpoint was the change in mean sitting systolic blood pressure (MSSBP) from baseline to week 8. Secondary endpoints included changes in mean sitting diastolic blood pressure (MSDBP), BP normalization rates, and response rates. Safety profile outcomes assessed treatment-emergent adverse events (TEAEs), laboratory parameters, and serious adverse events. At week 8, the KDF1901 group exhibited a significantly greater reduction in MSSBP (-22.8 ± 1.0 mmHg) compared with the dual therapy group (-16.7 ± 1.0 mmHg, P < 0.0001). Similarly, the mean MSDBP reduction was significantly greater with KDF1901 (P = 0.0006). BP normalization rates (75.9% vs 54.5%, P < .0001) and response rates (73.8% vs 51.7%, P < 0.0001) were significantly higher in the triple combination group. Overall, the incidence of TEAEs was similar between groups (24.7% vs 21.5%, P = 0.5783), with mild cases of dizziness were most commonly reported. Exploratory ad hoc analyses showed statistically greater changes in sodium, potassium, and uric acid levels with triple therapy, but clinically meaningful extreme electrolyte abnormalities were rare in both groups, and the overall laboratory profile remained acceptable. This trial reported that the single-pill triple combination KDF1901 significantly improved BP control compared with dual therapy without compromising tolerability. NCT07116863.

PMID 42259717
Read full article →
PubMedBMJ case reports2026-06-09

Hypokalaemic paralysis as a presenting feature of primary aldosteronism.

Khurana Shubham S, Kumar Vijay V, Adil Mohd M, Raj Neha N et al.

A woman in her 30s presented with acute flaccid paraparesis secondary to severe hypokalaemia. She had a known history of hypertension controlled on amlodipine and bisoprolol. Biochemical workup revealed metabolic alkalosis, renal potassium loss, suppressed plasma renin activity and markedly elevated aldosterone levels. CT imaging identified a left adrenal adenoma consistent with an aldosterone-producing adenoma. The patient underwent laparoscopic adrenalectomy, after which she no longer required antihypertensive medication and maintained normal serum potassium. This case highlights a reversible but often under-recognised cause of secondary hypertension presenting with hypokalaemic paraparesis.

PMID 42259571
Read full article →
PubMedThe Journal of investigative dermatology2026-06-09

The role of neutrophils and neutrophil extracellular traps in Staphylococcus aureus colonization in healthy and inflamed skin.

Riebelmann Jule J, Schittek Birgit B

Staphylococcus aureus (S aureus) commonly causes skin infections and is abundant on the skin of patients with atopic dermatitis, where it worsens inflammation and drives skin barrier defects. Neutrophils help to control S aureus infection through their antimicrobial activity and by recruiting other immune cells; however, they can also promote S aureus skin colonization. Excessive neutrophil activity and release of neutrophil extracellular traps may impair the skin barrier and thereby promote colonization. Moreover, S aureus has evolved strategies to evade neutrophil defenses. This review explores neutrophil-skin interactions in healthy and inflamed skin and potential therapeutic strategies targeting these interactions to reduce S aureus colonization in diseases like atopic dermatitis.

PMID 42262298
Read full article →
PubMedInjury2026-06-09

Peterson vs. Salter Harris physeal fracture classification systems: How consistent are they?

Charles-Lozoya Sergio S, Cobos-Aguilar Héctor H, Váldez-Cordova Carlos C, de la Parra-Márquez Miguel Leonardo ML et al.

The Salter-Harris (S-H) classification establishes five types of physeal fractures and is the most widely used to describe them. However, the Peterson classification includes fracture patterns not covered by the S-H classification, such as fractures crossing the metaphysis and extending to the physis and open injuries with loss of physis. Nonetheless, it is necessary to validate and compare its reliability with that of the S-H to enhance diagnostic possibilities and clinical interpretation. This study aimed to compare the consistency of intra and interobserver agreement of the S-H and Peterson classifications. A cross-sectional study was conducted to evaluate the reliability of 100 radiographs in the anteroposterior and lateral views. Five pediatric orthopedic surgeons and five third- and fourth-year orthopedic residents were asked to classify both fracture types on two occasions, with an eight-week interval between the two occasions. The intraobserver agreement for S-H in the expert and resident groups was κ = 0.66 and 0.61, respectively; for Peterson, it was κ = 0.67 and 0.61, respectively. The mean total agreement percentages for S-H and Peterson were 84.5% vs. 83.9%, respectively (t = 0.254; P = 0.8; Cohen's d = 0.20). The overall interobserver agreement for S-H in the first and second observations was κ = 0.57 and 0.63, respectively, and for Peterson, κ = 0.58 and 0.62, respectively. The S-H and Peterson classifications may have comparable reliability and moderate-to-substantial interobserver agreement, with no significant differences in overall agreement percentages.

PMID 42259041
Read full article →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-06-09

Development of All-Solid-State Sputtered S‑Scheme Heterojunction Photoanode for Stable and Efficient Solar-Driven Water Oxidation.

Shubham Kumar K, Ganesha Mukhesh K MK, Singh Ashutosh K AK

Scalable, clean hydrogen production via photoelectrochemical (PEC) water splitting is limited by poor light absorption and rapid charge recombination. Here, we report a rationally designed, all-solid-state plasmon-coupled S-scheme heterojunction photoanode, MoSe2/Au/TiO2, fabricated entirely through a scalable magnetron sputtering technique. The Initial MoSe2/TiO2 S-scheme heterojunction enhances light harvesting and achieves a photocurrent density of ∼0.25 mA/cm2 at 1.23 Vrhe, supported by a surface photovoltage of 223 mV and a carrier lifetime of 0.2 s. The strategic introduction of an ultrathin Au interlayer profoundly modifies the interface. This Au mediator established a stronger built-in electric field, a more favorable band alignment, maintained high redox potentials, enhanced light absorption, and improved photo-charge separation with transfer. This engineered MoSe2/Au/TiO2 heterojunction photoanode delivers a markedly superior performance, with a photocurrent density of ∼0.54 mA/cm2 at 1.23 Vrhe, a high surface photovoltage of 293.7 mV, and a prolonged carrier lifetime of 0.55 s, while maintaining stable operation over 6.5 h. Comprehensive experimental analysis, including in situ photoelectrochemical studies and spectroscopic characterization, systematically unveils the Au-mediated S-scheme mechanism, highlighting enhanced charge separation, reduced interfacial resistance, and preserved high redox potentials. This work establishes a scalable, robust S-scheme architecture for efficient solar-driven hydrogen generation.

PMID 42261205
Read full article →
PubMedScientific reports2026-06-09

Hybrid carbon matrices enable the suppression of polysulfide shuttle effect in Li-S batteries.

Kazymbetova Aizhan A, Kelgenbayeva Akbota A, Belgibayeva Ayaulym A, Nurpeissova Arailym A et al.

Lithium-sulfur (Li-S) batteries offer high theoretical energy density but face critical challenges due to sulfur's poor conductivity and the polysulfide shuttle effect. Here we report a novel cathode design utilizing a hybrid carbon matrix derived from buckwheat biomass and single-walled carbon nanotubes (SWCNT) to overcome these issues. The buckwheat-derived hard carbon (HC), obtained at 1000 °C, provides hierarchical porosity to anchor polysulfides and buffer sulfur expansion, while SWCNT (optimized at 6%) creates a conductive network. As a result, S@SP/HC/SWCNT cathode delivers an initial discharge capacity of ~ 1250 mAh g- 1 at 0.1 C and retains ~ 60% of this capacity after 100 cycles with ~ 100% Coulombic efficiency. Overall, this sustainable, low-cost, and scalable carbon-sulfur cathode architecture effectively addresses key Li-S challenges and demonstrates strong promise for practical high-energy, long-life Li-S batteries.

PMID 42260086
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about S-amlodipine gentisate